文献速递神经肿瘤

B7-H3 CAR-T细胞在H3G34突变弥漫性半球胶质瘤中展现强效抗肿瘤临床前疗效

Potent anti-tumor preclinical efficacy of B7-H3 CAR-T cells in H3G34-mutant, Diffuse Hemispheric Glioma.
PubMed 文献 · Neuro Oncol · 2026-08-10

本研究首次在临床前模型中评估靶向B7-H3的CAR-T细胞疗法对H3G34突变弥漫性半球胶质瘤(DHG)的疗效。B7-H3在DHG肿瘤和细胞系中高表达,而在正常脑组织中表达极低。B7-H3 CAR-T细胞在体外表现出抗原特异性细胞毒性,在三种DHG小鼠模型中瘤内注射可导致显著肿瘤消退和生存期延长,并实现持久肿瘤清除。

要点

  • B7-H3在DHG肿瘤中高表达,正常脑组织低表达,是潜在免疫治疗靶点
  • B7-H3 CAR-T细胞体外对DHG细胞有强效抗原特异性细胞毒性
  • 三种DHG小鼠模型中瘤内注射B7-H3 CAR-T细胞可显著缩小肿瘤并延长生存

核心结论

  • B7-H3 CAR-T细胞疗法在DHG临床前模型中高效,支持其作为DHG免疫治疗策略并推动临床转化。

研究设计与样本

  • 临床前研究:评估DHG患者标本和患者来源细胞系的B7-H3表达,构建两种B7-H3 CAR构建体,体外评估激活、细胞因子产生、耗竭和细胞毒性,并在多个原位DHG异种移植模型中评估疗效。

主要发现

  • B7-H3在DHG肿瘤和细胞系中高表达,正常脑组织中表达极低。
  • B7-H3 CAR-T细胞对DHG细胞显示强效抗原特异性细胞毒性,对B7-H3敲除DHG细胞活性可忽略。
  • 在三种DHG小鼠模型中,瘤内注射B7-H3 CAR-T细胞导致显著肿瘤消退和生存期大幅延长,并实现持久肿瘤清除。

临床怎么用

  • B7-H3 CAR-T细胞瘤内注射在临床前DHG模型中有效,支持向临床试验推进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse hemispheric glioma (DHG), H3 G34-mutant, is a highly aggressive and fatal pediatric brain tumor, with a median survival of only ∼18 months and no effective targeted therapies. While CAR T cell therapy has shown success in B-cell leukemia and promise in other pediatric CNS tumors, it has not yet been evaluated explicitly in preclinical or clinical models of DHG. B7-H3 (CD276), a tumor-associated antigen overexpressed in pediatric brain tumors, represents a promising target for immunotherapeutic intervention in DHG. Here, we present the first preclinical evaluation of B7-H3-directed CAR T cell therapy in DHG. METHODS: We evaluated B7-H3 expression in specimens from DHG patients and patient-derived cell lines. Two B7-H3-targeted CAR constructs were generated and evaluated for antigen-specific activation, cytokine production, exhaustion, and cytotoxicity in vitro. Therapeutic efficacy was assessed in multiple orthotopic DHG xenograft models, followed by multiplex immunofluorescence and serum cytokine profiling. RESULTS: B7-H3 was highly expressed in DHG tumors and cell lines, but at minimal levels in normal brain tissue. B7-H3 CAR T cells demonstrated potent, antigen-specific cytotoxicity against DHG cells, with negligible activity against B7-H3-knockout DHG cells. In vivo, the intratumoral administration of B7-H3 CAR T cells led to significant tumor regression and a substantial extension of survival in three DHG mouse models, with durable tumor eradication. CONCLUSION: This study provides preclinical evidence supporting B7-H3 CAR T cell therapy as a highly effective immunotherapeutic strategy for DHG. Our findings support B7-H3 as a compelling immunotherapeutic target for DHG, laying the groundwork for clinical translation. Diffuse hemispheric glioma (DHG) is an aggressive childhood brain tumor with limited treatment options and poor survival. In this study, we explored an immunotherapy approach using engineered immune cells, called CAR T cells, that specifically target a protein, B7-H3, found on tumor cells. We found that B7-H3 is highly present in DHG tumors but not in normal brain tissue. In brain tumor animal models, these CAR T cells effectively killed tumor cells, shrank tumors, and significantly extended survival. These findings offer promising evidence for a potential treatment option and support moving this approach toward clinical trials for children with DHG.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Akhavan D, Yadav M, Subham S, et al. Potent anti-tumor preclinical efficacy of B7-H3 CAR-T cells in H3G34-mutant, Diffuse Hemispheric Glioma. Neuro Oncol. 2026. PMID: 42573529. doi:10.1093/neuonc/noag185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。